Dopamine turnover in schizophrenia before and after haloperidol withdrawal: CSF, plasma, and urine studies

Neuropsychopharmacology

Volumn 15, Issue 1, 1996, Pages 75-86

  Beuger, M ^b   Van Kammen, D P ^a,b   Kelley, M E ^a   Yao, J ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Cerebrospinal fluid; Drug withdrawal; Haloperidol treatment; Homovanillic acid; Plasma; Schizophrenia; Urine

Indexed keywords

DOPAMINE; HALOPERIDOL; HOMOVANILLIC ACID; PLACEBO;

ADULT; CEREBROSPINAL FLUID; CONTROLLED STUDY; DRUG WITHDRAWAL; HOMEOSTASIS; HUMAN; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PLASMA; PRIORITY JOURNAL; RELAPSE; REVIEW; SCHIZOPHRENIA; URINE;

EID: 0030200676     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1016/0893-133X(95)00158-A     Document Type: Article

References (116)

1. Aizenstein ML, Korf J (1978): Aspects of influx and efflux of homovanillic acid of rat cerebrospinal fluid. Brain Res 149:129-140
2. Andèn NE, Brabowska-Andèn M (1983): Formation of deaminated metabolites of dopamine in noradrenaline neurons. Naunyn Schmiedebergs Arch Pharmacol 324:1-6
3. Ånggard E, Lewander T, Sjöqvist B (1974): Determination of homovanillic acid turnover in man. Life Sci 15:111-122
4. Åntelman SM, Knopf S, Caggiula A, Kocan D, Lysle DT, Edwards DJ (1988): Stress and enhanced dopamine utilization in the frontal cortex: The myth and reality. Ann N Y Acad Sci 537:262-272
5. Amin F, Davidson M, Davis KL (1992): Homovanillic acid measurement in clinical research: A review of methodology. Schizophr Bull 18:123-148
6. Bacapoulos NG, Maas JW, Hattox SE, Roth RH (1978): Regional distribution of dopamine metabolites in human and primate brain. Commun Psychopharmacol 2:281-286
7. Bagdy G, Perenyi A, Frecska E, Revai K, Papp Z, Fekete MIK, Arato M (1985): Decrease in dopamine, its metabolites and noradrenaline in cerebrospinal fluid of schizophrenic patients after withdrawal of long-term neuroleptic treatment. Psychopharmacology 85:62-64
8. Baker N, Kirch D, Waldo MC, Bell J, Adler LE, Hattox S, Murphy R, Freed man R (1991): Plasma homovanillic acid and prognosis in schizophrenia. Biol Psychiatr 29:192-196
9. BartkoG, Maylath E, Herczeg I (1987): Comparative study of schizophrenic patients relapsed on and off medication. Psychiatr Res 22:221-227
10. Binder S, Sivorinovsky G (1984): Measurement of urinary vanilmandelic acid and homovanillic acid by high-performance liquid chromatography with electrochemical detection following extraction by ion-exchange and ion-moderated partition. J Chromatogr 336:173-188
11. Borg S, Kvande H, Valverius P (1986): Clinical conditions and central dopamine metabolism in alcoholics during acute withdrawal under treatment with different pharmacological agents. Psychopharmacology 88:12-17
12. Bowers MB (1973): 5-Hydroxyindole acetic acid (5H-IAA) and homovanillic acid (HVA) following probenecid in acute psychotic patients treated with phenothiazines. Psychopharmacologia 28:309-318
13. Bowers MB (1974): Central dopamine turnover in schizophrenic syndromes. Arch Gen Psychiatr 31:50-54
14. Bowers MB, Heninger GR, Sternberg D, Meltzer HY (1980): Clinical processes and central dopaminergic activity in psychotic disorders. Commun Psychopharmacol 4:177-188
15. Breier A, Davis OR, Buchanan RW, Moricle LA, Munson RC (1993): Effects of metabolic perturbation on plasma homovanillic acid in schizophrenia. Relationship to prefrontal cortex volume. Arch Gen Psychiatr 50:541-550
16. Bunney WE Jr, Hamburg DA (1963): Methods for reliable longitudinal observation of behavior. Arch Gen Psychiatry 9:280-294
17. Carlsson A, Lindqvist M (1963): Effect of chlorpromazine and haloperidol on formation of 3-methoxytyramine and metanephrine in mouse brain. Acta Pharmacol Toxicol 20:140-144
18. Contreras SA, Maas JW, Seleshi E, Bowden CL (1987): Increase in human urine homovanillic acid concentration after neuroleptic treatment is the same with or without debrisoquin administration. Arch Gen Psychiatr 44:1109-1110
19. Contreras SA, Maas JW, Seleshi E, Bowden CL (1988): Urine and plasma levels of dopamine metabolites in response to apomorphine and neuroleptics in schizophrenics. Biol Psychiatr 24:818-822
20. Crowley TJ, Hoehn MM, Rutledge CO, Stallings MA, Heaton RK, Sundell S, Stilson D (1978): Dopamine excretion and vulnerability to drug-induced parkinsonism. Arch Gen Psychiatr 35:97-104
21. Csernansky JG, Faull K-F, Pfefferbaum A (1988a): Seasonal changes of CSF monoamine metabolites in psychiatric patients: What is the source? Psychiatr Res 25:361-363
22. Csernansky JG, Melletin J, Beauclair L, Lombrozo L (1988b): Mesolimbic dopaminergic supersensitivity following electrical kindling of the amygdala. Biol Psychiatr 35: 375-380
23. Culter NR, Jeste DV, Karoum F, Wyatt RJ (1982): Low-dose apomorphine reduces serum homovanillic acid concentrations in schizophrenic patients. Life Sci 30:753-756
24. Davidson M, Giordani AB, Mohs RC, Mykytyn VV, Platt S, Aryan ZS, Davis KL (1987): Control of exogenous factors affecting plasma homovanillic acid concentration. Psychiatr Res 20:307-312
25. Davidson M, Kahn RS, Powchik P, Warne P (1991): Changes in plasma homovanillic acid concentrations in schizophrenic patients following neuroleptic discontinuation. Arch Gen Psychiatr 48:73-76
26. Davidson M, Davis KL (1988): Comparison of plasma homovanillic acid concentrations in schizophrenic patients and normal controls. Arch Gen Psychiatr 45:561-563
27. Davila R, Manero E, Zumarraga M, Andia I, Schweitzer JW, Friedhoff AJ (1988): Plasma homovanillic acid as a predictor of response to neuroleptics. Arch Gen Psychiatr 45:564-567
28. Davis KL, Davidson M, Mohs RC, Kendler KS, Davis BM, Johns CA, DeNegris Y, Horvath TB (1985): Plasma homovanillic acid concentration and the severity of schizophrenic illness. Science 227:1601-1602
29. Davis KL, Kahn RS, KO G, Davidson M (1991): Dopamine in schizophrenia: A review and reconceptualization. Am J Psychiatr 148:1474-1486
30. Dawson ME, Nuechterlein KH, Schell AM, Gitlin M, Ventura J. (1994): Autonomic abnormalities in schizophrenia: state or trait indicators. Arch Gen Psychiatr 51:813-824
31. Doran AR, Boronow J, Weinberger DR, Wolkowitz OM, Breier A, Picker D (1987): Structural brain pathology in schizophrenia revisited: Prefrontal cortex pathology is inversely correlated with cerebrospinal fluid levels of homovanillic acid. Neuropsychopharmacology 1:25-32
32. Doran AR, Labarca R, Wolkowitz OM, Roy A, Douillet P, Pickar D (1990): Circadian variation of plasma homovanillic acid levels is attenuated by fluphenazine in patients with schizophrenia. Arch Gen Psychiatr 47:558-563
33. Elchisak MA, Polinsky RJ, Ebert MH, Powers KJ, Kopin IJ (1978): Contribution of plasma homovanillic acid (HVA) to urine and cerebrospinal fluid HVA in the monkey and its pharmacokinetic disposition. Life Sci 23:2339-2348
34. Elsworth JD, Leahy DJ, Roth RH, Redmond DE Jr (1987): Homovanillic acid concentrations in brain, CSF and plasma as indicators of central dopamine function in primates. J Neur Transm 68:51-62
35. Frecska E, Perenyi A, Bagdy G, Revai K (1985): CSF dopamine turnover and positive schizophrenic symptoms after withdrawal of long-term neuroleptic treatment. Psychiatr Res 16:221-226
36. Garelis E, Young SN, Lal S, Sourkes TL (1974): Monoamine metabolites in lumbar CSF: The question of their origin in relation to clinical studies. Brain Res 79:1-8
37. Gerhardt G, Drebing C, Freedman R (1986): Simultaneous determination of free homovanillic acid, (3-Methoxy-4-hydroxyphenyl) ethylene glycol, and vanilmandelic acid in human plasma by high-performance liquid chromatography coupled with dual-electrode coulometric electrochemical detection. Anal Chem 58:2879-2883
38. Glazer WM, Bowers MB, Charney DS, Heninger GR (1989): The effect of neuroleptic discontinuation on psychopathology, involuntary movements, and biochemical measures in patients with persistent tardive dyskinesia. Biol Psychiatr 26:224-233
39. Grenhoff J, Nisell M, Ferre S, Aston-Jones G, Svensson TH (1993): Noradrenergic modulation of midbrain dopamine cell firing elicited by stimulation of the locus coeruleus in the rat. J Neural Transm 93:11-25
40. Gur RE, Mozley PD, Resnick SM, Mozley LH, Shtasel DL, Gallagher F, Arnold SM, Karp JS, Alavi A, Reivich M, Gur RC (1995): Resting cerebral glucose metabolism in first-episode and previously treated patients with schizophrenia relates to clinical features. Arch Gen Psychiatr 52:657-667
41. Haroutunian V, Knott P, Davis KL (1988): Effects of mesocortical dopaminergic lesions upon subcortical dopaminergic function. Psychopharmacol Bull 24:341-344
42. Hoedtke R, Rogawski U, Wurtman RJ (1974): Effect of selective destruction of central and peripheral catecholamine-containing neurons with 6-hydroxydopamine on catecholamine excretion in the rat. Br J Pharmacol 51:265-270
43. Hornykiewicz O (1982): Brain catecholamines in schizophrenia - A good case for noradrenaline. Nature 299:484-486
44. Houston JP, Maas JW, Bowden CL, Contreras SA, McIntyre KL, Javors MA (1986): Cerebrospinal fluid HVA, central brain atrophy and clinical state in schizophrenia. Psychiatr Res 19:207-214
45. Hsiao JK, Colison J, Bartko JJ, Doran AR, Konicki PE, Potter WZ, Pickar D (1993): Monoamine neurotransmitter interactions in drug-free and neuroleptic-treated schizophrenics. Arch Gen Psychiatr 50:606-614
46. Javaid JI, Sharma RP, Janicak PG, Davis JM (1990): Plasma HVA in psychiatric patients: Longitudinal studies. Psychopharmacol Bull 26:361-365
47. Jennings WS, Schulz SC, Narasimhachari N, Hamer RM, Friedel RO (1985): Brain ventricular size and CSF monamine metabolites in an adolescent inpatient population. Psychiatr Res 16:87-94
48. Kahn RS, Davidson M (1993): On the value of measuring dopamine, norepinephrine and their metabolites in schizophrenia. Neuropsychopharmacology 8:93-95
49. Karoum F, Karson CN, Bigelow LB, Lawson WB, Wyatt RJ (1987): Preliminary evidence of reduced combined output of dopamine and its metabolites in chronic schizophrenia. Arch Gen Psychiatr 44:604-607
50. Karson CN, Garcia-Rill E, Biedermann J, Mrak RE, Husain MM, Skinner RD (1991): The brain stem reticular formation in schizophrenia. Psychiatry Res (Neuroimaging) 40:31-48
51. Kendler KS, Mohs RC, Davis KL (1983): The effects of diet and physical activity on plasma homovanillic acid in normal human subjects. Psychiatr Res 8:215-223
52. Kopin IJ, Oliver JA, Polinsky RJ (1988a): Relationship between urinary excretion of homovanillic acid and norepinephrine metabolites in normal subjects and patients with orthostatic hypotension. Life Sci 43:125-131
53. Kopin IJ, Bankiewicz KS, Harvey-White J (1988b): Assessment of brain dopamine metabolism from plasma HVA and MHPG during debrisoquin treatment: Validation in monkeys treated with MPTP. Neuropsychopharmacology 1:119-125
54. Koreen AR, Lieberman J, Alvir J, Mayerhoff D, Loebel A, Chakos M, Amin F, Cooper T (1994): Plasma homovanillic acid levels in first-episode schizophrenia. Arch Gen Psychiatr 51:132-138
55. Lambert GW, Eisenhofer G, Jennings GL, Esler MD (1993): Regional HVA production in humans. Life Sci 53:63-75
56. Lambert GW, Eisenhofer G, Esler MD (1994): The influence of aging on the plasma concentration and renal clearance of homovanillic acid. Psychoneuroendocrinology 19:33-41
57. Lewine RR, Risch SC, Risby E, Stripetic M, Jewart D, Eccard M, Caudle J, Pollard W (1991): Lateral ventricle-brain ratio and balance between CSF HVA and 5-HIAA in schizophrenia. Am J Psychiatr 148:1189-1194
58. Lindström LH (1985): Low HVA and normal 5-HIAA CSF levels in drug-free schizophrenic patients compared to healthy volunteers: Correlations to symptomatology and family history. Psychiatr Res 14:265-273
59. Linnoila M, Oliver J, Adinoff B, Potter WZ (1988): High correlations of norepinephrine, dopamine, and epinephrine and their major metabolic excretion rates. Arch Gen Pyschiatr 45:701-704
60. Lipska BK, Jaskiw GE, Chrapusta S, Karoum F, Weinberger DR (1992): Ibotenic acid lesion of the ventral hippocampus differentially affects dopamine and its metabolites in the nucleus accumbens and prefrontal cortex in the rat. Brain Res 585:1-6
61. Lipska BK, Weinberger DR (1993); Delayed effects of neonatal hippocampal damage on haloperidol-induced catalepsy and apomorphine-induced stereotypic behaviors in the rat. Dev Brain Res 75:312-222
62. Lipska BK, Jaskiw GE, Weinberger DR (1994): The effects of combined prefrontal cortical and hippocampal damage on dopamine-related behaviors in rats. Pharmacol Biochem Behav 48:1053-1057
63. Lipska BK, Chrapusta SJ, Egan MF, Weinberger DR (1996) (in press, a): Neonatal excitotoxic ventral hippocampal damage alters dopamine response to mild repeated stress and to chronic haloperidol. Synapse.
64. Lipska BK, Jaskiw GE, Braun AR, Weinberger DR (1996) (in press, b): Prefrontal cortical and hippocampal modulation of haloperidol-induced catalepsy and apomorphine-induced stereotypic behaviors in the rat. Biol Psychiatr
65. Losonczy MF, Song IS, Mohs RC, Mathé AA, Davidson M, David BM, Davis KL (1986): Correlates of lateral ventricular size in chronic schizophrenia: II. Biological measures. Am J Psychiatr 143:1113-1118
66. Maas, JW, Hattox SE, Martin DM, Landis DH (1979): A direct method for determining dopamine synthesis and output of dopamine metabolites from brain in awake animals. J Neurochem 32:839-843
67. Maas JW, Contreras SA, Seleshi E, Bowden CL (1988): Dopamine metabolism and disposition in schizophrenic patients: Studies using debrisoquin. Arch Gen Psychiatr 45:553-559
68. Maas JW, Contreras SA, Miller AL, Berman N, Bowden CL, Javors MA, Seleshi E, Weintraub SE (1993a): Studies of catecholamine metabolism in schizophrenia/psychosis: I. Neuropsychopharmacology 8:97-109
69. Maas JW, Contreras SA, Miller AL, Berman N, Bowden CL, Javors MA, Seleshi E, Weintraub SE (1993b): Studies of catecholamine metabolism in schizophrenia/psychosis-II. Neuropsychopharmacology 8:111-116
70. Meltzer HY (1991): The mechanism of action of novel antipsychotic drugs. Schizophr Bull 17:263-287
71. Miller AL, Keenan RW, Maas JW, Asch RH (1987): Disposition of homovanillic acid in the primate. Metabol Brain Dis 2:207-212
72. Moleman P, Bruinvels J, van Valkenburg CFM (1978): Haloperidol inhibits the disappearance of acidic metabolites from the rat striatum. J Pharm Pharmacol 30:583-585
73. Muscettola G, Barbato G, de-Bartolomeis A, Monteleone P, Pickar D (1990): Plasma HVA, tardive dyskinesia and psychotic symptoms in long-term drug-free inpatients with schizophrenia. Psychiatr Res 33:259-267
74. Nybåck H, Berggren B-M, Hindmarsh I, Sedvall G, Wiesel F-A (1983): Cerebroventricular size and cerebrospinal fluid monoamine metabolites in schizophrenic patients and healthy volunteers. Psychiatr Res 9:301-308
75. Pandey RS, Rao BSS, Subash MN, Subba Krishinu DK, Srinivas KN (1987): Central dopamine and serotonin turnover in schizophrenia. Ind J Psychiatr 29:203-212
76. Pickar D (1988): Perspectives on a time-dependent model of neuroleptic action. Schizophr Bull 14:255-268
77. Pickar D, Labarca RE, Doran AR, Wolkowitz OM, Roy A, Breier A, Linnoila M, Paul SM (1986): Longitudinal measurement of plasma homovanillic acid levels in schizophrenic patients: Correlation with psychosis and response to neuroleptic treatment. Arch Gen Psychiatr 43:669-676
78. Pickar D, Breier A, Hsiao JK, Doran AR, Wolkowitz OM, Pato CN, Konicki PE, Potter WZ (1990): Cerebrospinal fluid and plasma monoamine metabolites and their relation to psychosis: Implications for regional brain dysfunction in schizophrenia. Arch Gen Psychiatr 47:641-648
79. Post RM, Fink E, Carpenter WT, Goodwin FK (1975): Cerebrospinal fluid amine metabolites in acute schizophrenia. Arch Gen Psychiatr 32:1063-1069
80. Potter WZ, Rudorfer MV, Pickar D, Linnoila M (1984): Effects of psychotropic drugs on neurotransmitters in man. Life Sci 41:817-820
81. Pycock CJ, Kerwin RW, Carter CJ (1980): Effect of lesion of cortical dopamine terminals on subcortical dopamine in rats. Nature 186:74-75
82. Randrup A, Munkvad I (1972): Evidence indicating an association between schizophrenia and dopamine hyperactivity in the brain. Orthomol Psychiatr 1:2
83. Rimon R, Roos BE, Rakkolainen V, Alanen Y (1971): The content of 5-hydroxyindoleacetic acid and homovanillic acid in the cerebrospinal fluid of patients with acute schizophrenia. J Psychosom Res 15:375-378
84. Scatton B, Worms P, Lloyd KG, Bartholini G (1982): Cortical modulation of striatal function. Brain Res 232:331-343
85. Scheinin H (1986): Enhanced noradrenergic neuronal activity increases homovanillic acid levels in cerebrospinal fluid. J Neurochem 47:665-667
86. Scheinin M, Chang W-H, Kirk JL, Linnoila M (1983): Simultaneous determination of 3-methoxy-4-hydroxyphenyl-glycol 5-hydroxyindolacetic acid, and homovanillic acid in CSF with high performance liquid chromatography using electrochemical detection. Anal Biochem 131:246-253
87. Sedvall G, Wode-Helgodt B (1980): Aberrant monoamine metabolite levels in cerebrospinal fluid and family history of schizophrenia: Their relationship in schizophrenic patients. Arch Gen Psychiatr 37:1113-1116
88. 4. Neuropsychopharmacology 7:261-284
89. Sharma RP, Javaid JI, Janicak PG, Comaty J, Davis JM (1989): Plasma and CSF HVA before and after pharmacological treatment. Psychiatr Res 28:97-104.
90. Sharma RP, Javaid JI, Janicak PG, Davis JM, Fauli K (1993): HVA in the CSF: Pattern of response after 4 weeks of neuroleptic treatment. Biol Psychiatr 34:128-134
91. Sourkes TL (1973): On the origin of homovanillic acid (HVA) in the cerebrospinal fluid. J Neural Transm 34:153-157
92. Spitzer RL, Endicott J (1979): The Schedule for Affective Disorders and Schizophrenia-Lifetime version, ed 3. New York, New York State Psychiatric Institute, Biometrics Research
93. Stanley M, Traskman-Bendz L, Dorovini-Zis K (1985): Correlation between aminergic metabolites simultaneously obtained from human CSF and brain. Life Sci 37:1279-1286
94. Sternberg DE, Heninger GR, Roth RH (1983): Plasma homovanillic acid as an index of brain dopamine metabolism: Enhancement with debrisoquin. Life Sci 32:2447-2452
95. Tandon R, Shipley JE, Greden JF, Mann MA, Eisner WH, Goodson J (1991): Muscarinic cholinergic overactivity in schizophrenia: Relationship to positive and negative symptoms. Schizophr Res 4:23-30
96. van Kammen DP (1979): The dopamine hypothesis of schizophrenia revisited. Psychoneuroendocrinology 4:37-46
97. van Kammen DP (1991): The biochemical basis of relapse and drug response in schizophrenia: Review and hypothesis. Psychol Med 21:881-895
98. van Kammen DP, Sternberg DE (1980): CSF studies in schizophrenia. In Wood JH (ed), Neurobiology of Cerebrospinal Fluid, vol I, New York, Plenum, pp 719-742
99. van Kammen DP, van Kammen WB (1984): The amphetamine challenge test in schizophrenia: A stress response? In Usdin E, Kvetnansky R, Axelrod J (eds), Stress: The Role of Catecholamines and Other Neurotransmitters, New York, Gordon & Breach, pp 957-966
100. van Kammen DP, Docherty JP, Bunney WE Jr (1982a): Prediction of early relapse after pimozide discontinuation by response to d-amphetamine during pimozide treatment. Biol Psychiatr 17:233-242
101. van Kammen DP, Sternberg DE, Hare TA, Waters R, Bunney WE Jr (1982b): CSF levels of gamma-aminobutyric acid in schizophrenia. Arch Gen Psychiatr 39:91-97
102. van Kammen DP, Mann LS, Sternberg DE, Scheinin M, Ninan PT, Marder SR, van Kammen WB, Rieder RO, Linnoila M (1983): Dopamine beta hydroxylase activity and homovanillic acid in spinal fluid of schizophrenics with brain atrophy. Science 220:974-976
103. van Kammen DP, van Kammen WB, Mann LS, Seppala T, Linnoila M (1986): Dopamine metabolism in the cerebrospinal fluid of drug-free schizophrenic patients with and without cortical atrophy. Arch Gen Psychiatr 43: 978-983
104. van Kammen DP, Peters JL, van Kammen WB, Nugent A, Goetz KL, Yao J, Linnoila M (1989): CSF norepinephrine in schizophrenia is elevated prior to relapse after haloperidol withdrawal. Biol Psychiatr 26:176-181
105. van Kammen DP, Kelley ME, Gurklis J, Gilbertson MW, Yao JK, Peters JL (1995): Behavioral vs. biochemical prediction of relapse following haloperidol withdrawal in schizophrenia. Arch Gen Psychiatr 52:673-678
106. van Kammen DP, Kelley ME, Gurklis JA, Gilbertson MW, Yao JK, Condray R, Peters JL (1996): Predicting duration of clinical stability following haloperidol withdrawal in schizophrenia. Neuropsychopharmacology 14:275-283
107. van Kammen DP, Petty F, Kramer GL, Kelley ME, Yao JK, Gurklis JA, Peters JL (submitted): Clinical evidence that GABA is involved in schizophrenia: Plasma GABA correlates with brain morphology, CSF HVA, CSF 5-HIAA, negative symptoms, and premorbid functioning.
108. van Rossum JM (1966): The significance of dopamine-receptor blockade for the mechanism of action of neuroleptic drugs. Arch Int Pharmacodynamics 160:492-494
109. Weinberger DR (1987): Implications of normal brain development for the pathogenesis of schizophrenia. Arch Gen Psychiatr 44:660-669
110. Weinberger DR, Berman KF, Illowsky BP (1988): Physiological dysfunction of dorsolateral prefrontal cortex in schizophrenia. III. A new cohort and evidence for a monoaminergic mechanism. Arch Gen Psychiatr 45:609-615
111. Westerink BHC, Kikkert RJ (1986): Effects of various centrally acting drugs on the efflux of dopamine metabolites from the rat brain. J Neurochem 46:1145-1152
112. Whelton CL, Gupta RN, Cleghorn JM, Ballagh SR (1993): Influence of renal clearance on peripheral homovanillic acid measurements in healthy subjects and schizophrenic patients. Special issue dedicated to the memory of Professor John M. Cleghorn. Schizophr Res 11:33-40
113. Yeomans JS (1995): Role of tegmental cholinergic neurons in dopaminergic activation, antimuscarinic psychosis and schizophrenia. Neuropsychopharmacology 12:3-16
114. Zahn TP (1988): Studies of autonomic psychophysiology and attention in schizophrenia. Schizophr Bull 14:205-208
115. Zander KJ, Fischer B, Zimmer R, Ackenheil M (1981): Long-term neuroleptic treatment of chronic schizophrenic patients: Clinical and biochemical effects of withdrawal. Psychopharmacology 33:43-47
116. Zukin SR, Javitt DC (1992): The PCP/NMDA theory of schizophrenia. In Lindenmayer J-P, Kay SR (eds), New Biological Vistas on Schizophrenia, New York, Brunner/ Mazel, pp 222-238